BEFORE & AFTER PHOTOS
The proof is in the pictures—MetroGel® 1% delivers visible results*
These actual unretouched photos tell the Oracea® story better than words.
Individual Results May Vary.
The patients depicted on these "before and after" photographs were actual participants in the clinical trials for Oracea®
studies 301 and 302.
Study 301:
Patient ID#: 301.115
 |
 |
| Baseline |
After 16 weeks of treatment with Oracea® |
This study was Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Oracea, in which patients received 40 mg of Oracea or a placebo for 16 weeks.
Study 302:
Patient ID#: 302.1009
 |
 |
| Baseline |
After 16 weeks of treatment with Oracea® |
Patient ID#: 302.4023
 |
 |
| Baseline |
After 16 weeks of treatment with Oracea® |
Patient ID#: 302.4030
 |
 |
| Baseline |
After 16 weeks of treatment with Oracea® |
This study was Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Oracea, in which patients received 40 mg of Oracea or a placebo for 16 weeks.
Reference:
1) Del Rosso JQ, Webster, GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802.